Antihistamines barely touch eczema itch, review finds

Oral antihistamines are one of the most reflexive add-ons in eczema care, taken on the assumption that blocking histamine will calm itch and rescue sleep. They are cheap, widely available without prescription, and often recommended informally for the night-time scratching that makes atopic dermatitis so wearing. But the underlying question — whether they actually change the course of the disease or the intensity of the itch — has never been resolved by pooling the randomised evidence properly. This review set out to synthesise both the benefits and the harms of add-on antihistamines across the whole trial literature.

The authors ran a systematic review and Bayesian random-effects network meta-analysis of randomised trials, searching Medline, Embase, CENTRAL and the US Food and Drug Administration and European Medicines Agency databases from inception to 5 May 2025. Eligible trials tested add-on oral H1 antihistamines, H2 blockers, mast cell stabilisers such as nedocromil sodium and sodium cromoglycate, or combinations. Paired reviewers screened, extracted data and assessed risk of bias with a modified Cochrane tool. Outcomes were eczema severity on oSCORAD (0-83, minimal important difference 8.2), itch on a 0-10 numerical rating scale (minimal important difference 3), sleep disturbance, disease-related quality of life and harms, with certainty rated using GRADE. In total, 47 trials enrolling 6230 children and adults, mostly with moderate to severe disease, were included.

Compared with placebo, adding a first- or second-generation H1 antihistamine likely produced a small reduction in eczema severity (mean difference -1.87, 95% credible interval -3.47 to -0.27) and in itch severity (-0.89, -1.41 to -0.37), both with moderate certainty. Crucially, both effects sit well below the minimal important differences of 8.2 and 3 respectively, meaning they are statistically detectable but not the size of change a patient would identify as mattering. With low certainty, none of the studied interventions appeared to improve sleep disturbance or reduce eczema exacerbations. First-generation agents probably increase cognitive impairment and may increase discontinuation for adverse events (risk difference 66 more per 1000, 95% credible interval 0 to 231 more). Cognitive-impairment risk varied among second-generation drugs, from 0 more per 1000 for loratadine to 16 for levocetirizine and 17 for cetirizine.

This contradicts a long-standing habit rather than a strong evidence base: the routine use of antihistamines in eczema grew from plausibility and sedation rather than from demonstrated disease control. By combining a full network of trials with formal certainty ratings, the review turns a vague suspicion into a reasonably firm conclusion that the benefit is real but clinically unimportant, while the harms of older sedating agents are not. The authors state the findings provide evidence against routine antihistamine use and will inform updated clinical guidelines. Open questions include whether specific subgroups, such as people with milder disease or coexisting allergic conditions, behave differently, and how the drugs perform alongside modern topical and biologic therapies.

If you have been taking an oral antihistamine mainly to control eczema itch or to sleep through it, this is a reason to think the drug is doing far less than assumed. The measured improvements exist but are smaller than the change a person would notice, and the pooled evidence did not show better sleep or fewer flares. The older sedating antihistamines carry a probable cost in cognitive impairment, and even among newer ones the estimates differ. That makes this a sensible thing to raise with whoever manages your skin, rather than a reason to change anything on your own.